Drug Trial Radar · NCT05527184
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
256
Actual
Start
Jan 11, 2023
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.
Conditions
- Endometrial Cancer
- High Grade Serous Adenocarcinoma of Ovary
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
- Cervical Cancer
Interventions
IMGN151Drug
IMGN151 is an antibody-drug conjugate (ADC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 3 years
- Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Day 21 of Cycle 1 (Cycle length = 3 weeks)
- Recommended Dose of IMGN151 MonotherapyTime frame: Up to approximately 2 years
Locations
58 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham /ID# 269045
Birmingham, Alabama
City of Hope National Medical Center /ID# 269036
Duarte, California
Moores Cancer Center /ID# 269040
La Jolla, California
University of California Los Angeles Medical Center /ID# 269037
Los Angeles, California
Hoag Memorial Hospital Presbyterian /ID# 269047
Newport Beach, California
UCHSC Anschultz Cancer Pavilion /ID# 269056
Aurora, Colorado
AdventHealth Celebration /ID# 269030
Kissimmee, Florida
Mount Sinai Medical Center /ID# 269050
Miami, Florida
Miami Cancer Institute at Baptist Health /ID# 269041
Miami, Florida
Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055
Sarasota, Florida
University of Chicago Medical Center /ID# 269028
Chicago, Illinois
Massachusetts General Hospital /ID# 278119
Boston, Massachusetts
Dana-Farber Cancer Institute /ID# 269039
Boston, Massachusetts
Karmanos Cancer Institute - Detroit /ID# 269052
Detroit, Michigan
University of Mississippi Medical Cancer Center /ID# 269046
Jackson, Mississippi
Washington University School of Medicine - St. Louis /ID# 269048
St Louis, Missouri
Holy Name Medical Center /ID# 269051
Teaneck, New Jersey
Roswell Park Cancer Institute /ID# 269043
Buffalo, New York
Long Island Jewish Medical Center /ID# 269035
New Hyde Park, New York
Columbia University Irving Medical Center /ID# 269033
New York, New York
University of Rochester Medical Center /ID# 269044
Rochester, New York
University of North Carolina Medical Center /ID# 269027
Chapel Hill, North Carolina
Atrium Health Levine Cancer Institute /ID# 269049
Charlotte, North Carolina
The Ohio State University Comprehensive Cancer Center /ID# 269026
Columbus, Ohio
OU Health - Stephenson Cancer Center /ID# 269025
Oklahoma City, Oklahoma
University of Pennsylvania /ID# 269042
Philadelphia, Pennsylvania
West Penn Hospital /ID# 269054
Pittsburgh, Pennsylvania
Women & Infants Hospital /ID# 269032
Providence, Rhode Island
Sanford Cancer Center /ID# 269038
Sioux Falls, South Dakota
Tennessee Oncology Nashville /ID# 269029
Nashville, Tennessee
MD Anderson Houston /ID# 269057
Houston, Texas
University of Virginia /ID# 269053
Charlottesville, Virginia
Monash Health - Monash Medical Centre /ID# 268971
Perth, Western Australia, Australia
Hôpital Vivalia De Libramont /ID# 268979
Libramont-Chevigny, Luxembourg, Belgium
Universitair Ziekenhuis Leuven /ID# 268977
Leuven, Vlaams-Brabant, Belgium
Cross Cancer Institute /ID# 268984
Edmonton, Alberta, Canada
BC Cancer - Kelowna /ID# 268983
Kelowna, British Columbia, Canada
Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 268982
Montreal, Quebec, Canada
Centre Hospitalier Universite De Sherbrooke - Hôtel-Dieu Hospital /ID# 268981
Sherbrooke, Quebec, Canada
Institut Gustave Roussy /ID# 268994
Villejuif, Île-de-France Region, France
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.